ValueAct Pays a Price for Its Supporting Role at Valeant
Article Featured on New York Times | By Andrew Ross Sorkin Bill Ackman gets a lot of ink and a lot of criticism as one of the largest investors behind the crisis-ridden Valeant Pharmaceuticals. But another activist investment firm with a much larger role in Valeant’s activities has largely gone unquestioned: ValueAct, a San Francisco based investor […]